The company noted the new translational data presented at ESDR provide novel and differentiated mechanistic insights into IL-13Rα1 mediated cytokine signaling in atopic dermatitis (AD).
First poster data showed increased IL-13Rα1 expression on mast cells and eosinophils in skin samples from atopic dermatitis (AD) patients, reinforcing the central role of IL-13Rα1.
Eblasakimab significantly reduced neuronal itch sensitization caused by distinct IL-4 and IL-13 itch pathways.
An emerging role of IL-13Rα1 signaling in mediating neuronal excitability and sensitivity beyond AD was identified.
Earlier this month, ASLAN announced a new clinical trial of eblasakimab for moderate-to-severe atopic dermatitis (AD) in adult patients who have previously been treated with dupilumab.
Dubbed TREK-DX trial, the study is expected to enroll the first patient in the fourth quarter of 2022.
In January 2022, ASLAN initiated the TREK-AD Phase 2b trial to evaluate the safety and efficacy of eblasakimab in moderate-to-severe AD patients. Topline data is expected in the first half of 2023.
Price Action: ASLN shares are up 1.64% at $0.62 on the last check Wednesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.